Nanobiotix S.A. American Depositary Shares (NBTX) Financials
Key financial figures for Nanobiotix S.A. American Depositary Shares (Q4 2025), as reported in EUR.
Nanobiotix S.A. reported revenue of 3.0 million EUR for Q4 FY2025, down 90.9% from the same period a year earlier. The company posted a net loss of 18.6 million EUR, or -0.39 EUR per share. Operating margin came to -386.89%, against -4.28% a year earlier. Free cash flow for the period was -16.4 million EUR. Across the last 5 reported quarters, quarterly revenue has moved from 32.9 million EUR in Q4 FY2023 to 3.0 million EUR in Q4 FY2025. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Nanobiotix S.A. are on the SentiSense financials page.
- Revenue
- EUR 3M
- Net Income
- -EUR 19M
- EPS
- EUR -0.39
- Total Assets
- EUR 68M
- Operating Cash Flow
- -EUR 16M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q4 FY2025 | EUR 3M | -EUR 19M | -EUR 0.39 | -386.89% | -EUR 16M |
| Q2 FY2025 | EUR 27M | -EUR 5M | -EUR 0.11 | 3.03% | -EUR 18M |
| Q4 FY2024 | -EUR 16M | -EUR 46M | -EUR 0.98 | -EUR 14M | |
| Q2 FY2024 | EUR 9M | -EUR 22M | -EUR 0.46 | -254.62% | -EUR 6M |
| Q4 FY2023 | EUR 33M | -EUR 12M | -EUR 0.31 | -4.28% | EUR 5M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | EUR 30M | -EUR 24M | -EUR 0.50 | -36.49% | -EUR 34M |
| FY2024 | -EUR 7M | -EUR 68M | -EUR 1.44 | -EUR 20M | |
| FY2023 | EUR 36M | -EUR 40M | -EUR 1.08 | -73.96% | -EUR 13M |
Frequently asked questions
What was Nanobiotix S.A.'s revenue last quarter?
Nanobiotix S.A. reported revenue of 3.0 million EUR for Q4 FY2025, down 90.9% from the same period a year earlier.
Is Nanobiotix S.A. profitable?
Not in its most recent reported period. Nanobiotix S.A. reported a net loss of 18.6 million EUR for Q4 FY2025, a net margin of -618.24% on revenue.
How has Nanobiotix S.A.'s margin trended?
Operating margin was -386.89% in Q4 FY2025, compared with -4.28% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
When does Nanobiotix S.A. report next?
Nanobiotix S.A. is scheduled to report results on 2026-09-29. The company has confirmed that date.
Figures are as reported by the filer in EUR and are not converted to US dollars. The share price is quoted in US dollars, so the two are not directly comparable.
Full income statement, balance sheet and cash flow for Nanobiotix S.A. American Depositary Shares on SentiSense, with up to forty quarters and twenty fiscal years of history.